NO20006194D0 - Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri - Google Patents

Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri

Info

Publication number: NO20006194D0
Authority: NO; Norway
Prior art keywords: treatment; bowel syndrome; irritable bowel; functional dyspepsia; pharmaceutical composition
Prior art date: 1998-06-11

Application number

NO20006194A

Other languages

English (en)

Other versions

NO327738B1 (no

NO20006194L (no

Inventor

Per Hellstroem

Suad Efendic

Original Assignee

Per Hellstroem

Suad Efendic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-11

Filing date

2000-12-06

Publication date

2000-12-06

2000-12-06 Application filed by Per Hellstroem, Suad Efendic filed Critical Per Hellstroem

2000-12-06 Publication of NO20006194D0 publication Critical patent/NO20006194D0/no

2001-01-25 Publication of NO20006194L publication Critical patent/NO20006194L/no

2009-09-14 Publication of NO327738B1 publication Critical patent/NO327738B1/no

Links

201000006549 dyspepsia Diseases 0.000 title abstract 4
208000002551 irritable bowel syndrome Diseases 0.000 title abstract 4
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
239000000126 substance Substances 0.000 title 1
230000001262 anti-secretory effect Effects 0.000 abstract 3
239000003626 gastrointestinal polypeptide Substances 0.000 abstract 3
210000001035 gastrointestinal tract Anatomy 0.000 abstract 3
239000005556 hormone Substances 0.000 abstract 3
229940088597 hormone Drugs 0.000 abstract 3
230000002586 relaxatory effect Effects 0.000 abstract 3
210000002460 smooth muscle Anatomy 0.000 abstract 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
102100040918 Pro-glucagon Human genes 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
239000000654 additive Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NO20006194A 1998-06-11 2000-12-06 Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning NO327738B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9802080A SE9802080D0 (sv)	1998-06-11	1998-06-11	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
PCT/SE1999/000997 WO1999064060A1 (en)	1998-06-11	1999-06-08	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (3)

Publication Number	Publication Date
NO20006194D0 true NO20006194D0 (no)	2000-12-06
NO20006194L NO20006194L (no)	2001-01-25
NO327738B1 NO327738B1 (no)	2009-09-14

Family

ID=20411665

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006194A NO327738B1 (no)	1998-06-11	2000-12-06	Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning

Country Status (19)

Country	Link
US (1)	US6348447B1 (no)
EP (2)	EP1405642A1 (no)
JP (2)	JP2002517468A (no)
AT (1)	ATE252912T1 (no)
AU (1)	AU738994B2 (no)
CA (1)	CA2321700C (no)
CZ (1)	CZ300873B6 (no)
DE (1)	DE69912434T2 (no)
DK (1)	DK1094834T3 (no)
ES (1)	ES2205845T3 (no)
HU (1)	HUP0103147A3 (no)
NO (1)	NO327738B1 (no)
NZ (1)	NZ506163A (no)
PL (1)	PL198802B1 (no)
PT (1)	PT1094834E (no)
RU (1)	RU2226402C2 (no)
SE (1)	SE9802080D0 (no)
WO (1)	WO1999064060A1 (no)
ZA (1)	ZA200004080B (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
DK1808438T3 (da)	1999-06-29	2014-10-27	Mannkind Corp	Rensning og stabilisering af peptid og proteiner i lægemidler
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
CN1487836A (zh)	2000-03-14	2004-04-07	埃米林药品公司	胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
EP2213743A1 (en)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albumin fusion proteins
CN103356996A (zh) *	2000-05-19	2013-10-23	埃米林药品公司	Glp-1用于制备治疗急性冠脉综合征的药物的用途
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
PL209734B1 (pl)	2002-02-20	2011-10-31	Emisphere Tech Inc	Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
DK1641823T3 (da)	2003-06-12	2011-12-12	Lilly Co Eli	GLP-1-analog fusionsproteiner
DK1633774T3 (da)	2003-06-18	2010-05-25	Tranzyme Pharma Inc	Makrocykliske motilinreceptorantagonister
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US20090305964A1 (en) *	2005-04-21	2009-12-10	Gastrotech Pharma A/S	Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
CA2608311C (en)	2005-05-13	2012-11-27	Eli Lilly And Company	Glp-1 pegylated compounds
CN101258163B (zh)	2005-06-30	2013-08-21	益普生制药股份有限公司	Glp-1药物组合物
JP4994374B2 (ja) *	2005-07-29	2012-08-08	ジオファームオンコロジー，インコーポレイテッド	がんを治療するための化合物および方法
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (no)	2006-02-22	2015-07-10	Mannkind Corp
MX2009006942A (es) *	2006-12-29	2009-11-09	Ipsen Pharma Sas	Composiciones farmaceuticas de glp-1.
WO2008134425A1 (en) *	2007-04-27	2008-11-06	Cedars-Sinai Medical Center	Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
WO2009055742A2 (en) *	2007-10-24	2009-04-30	Mannkind Corporation	Delivery of active agents
JP2011500850A (ja) *	2007-10-24	2011-01-06	マンカインドコーポレイション	Ｇｌｐ−１による副作用を防止する方法
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8765669B2 (en)	2008-06-17	2014-07-01	Glytech, Inc.	Glycosylated GLP-1 peptide
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP-1 analogues pharmaceutical compositions
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
US8614185B2 (en)	2009-05-04	2013-12-24	Centocor Ortho Biotech Inc.	Fusion proteins of alpha-MSH derivatives and Fc
WO2010129248A1 (en)	2009-05-06	2010-11-11	Centocor Ortho Biotech Inc.	Melanocortin receptor binding conjugates
CN104721825B (zh)	2009-06-12	2019-04-12	曼金德公司	具有确定比表面积的二酮哌嗪颗粒
SG177592A1 (en) *	2009-07-29	2012-02-28	Daiichi Sankyo Co Ltd	Motilin-like peptide compound having transmucosal absorbability imparted thereto
KR20120101037A (ko)	2009-10-30	2012-09-12	오츠카 가가쿠 가부시키가이샤	항원성 ｇｌｐ?１ 아날로그의 당쇄 부가체
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
WO2011123943A1 (en)	2010-04-09	2011-10-13	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
CN107129538B (zh)	2010-04-27	2021-07-16	西兰制药公司	Glp-1受体激动剂和胃泌素的肽缀合物及其用途
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
JP2013530993A (ja)	2010-07-02	2013-08-01	アンジオケムインコーポレーテッド	治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
SI2651398T1 (en)	2010-12-16	2018-04-30	Novo Nordisk A/S	SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
PL2696687T3 (pl)	2011-04-12	2017-06-30	Novo Nordisk A/S	Pochodne podwójnie acylowanej GLP-1
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
HRP20181447T1 (hr)	2012-03-22	2018-11-02	Novo Nordisk A/S	Pripravci glp-1 peptida i njihova priprava
PT2827845T (pt)	2012-03-22	2019-03-29	Novo Nordisk As	Composições compreendendo um agente de entrega e sua preparação
ES2965469T3 (es)	2012-03-22	2024-04-15	Novo Nordisk As	Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
IN2015DN00544A (no)	2012-07-23	2015-06-26	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
KR102272671B1 (ko)	2013-05-02	2021-07-06	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
CN104371019B (zh)	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
PL3057984T3 (pl)	2013-10-17	2018-12-31	Zealand Pharma A/S	Acylowane analogi glukagonu
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
KR101825048B1 (ko)	2014-12-31	2018-02-05	주식회사 제넥신	GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
PT3257524T (pt)	2015-02-11	2020-11-27	Gmax Biopharm Llc	Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica
DK3283507T3 (da)	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
EP3551651B1 (en)	2016-12-09	2024-03-06	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
JP6898518B2 (ja)	2018-02-02	2021-07-07	ノヴォノルディスクアー／エス	Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CN117126279A (zh)	2018-03-20	2023-11-28	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh)	2019-09-18	2021-03-19	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN119744271A (zh)	2022-09-08	2025-04-01	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY147327A (en) *	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
US5994500A (en) *	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides

1998
- 1998-06-11 SE SE9802080A patent/SE9802080D0/xx unknown
1999
- 1999-06-08 NZ NZ506163A patent/NZ506163A/en unknown
- 1999-06-08 ES ES99930089T patent/ES2205845T3/es not_active Expired - Lifetime
- 1999-06-08 AT AT99930089T patent/ATE252912T1/de not_active IP Right Cessation
- 1999-06-08 DE DE69912434T patent/DE69912434T2/de not_active Expired - Lifetime
- 1999-06-08 EP EP20030024624 patent/EP1405642A1/en not_active Withdrawn
- 1999-06-08 PT PT99930089T patent/PT1094834E/pt unknown
- 1999-06-08 CZ CZ20004491A patent/CZ300873B6/cs not_active IP Right Cessation
- 1999-06-08 AU AU46697/99A patent/AU738994B2/en not_active Ceased
- 1999-06-08 RU RU2000133249/14A patent/RU2226402C2/ru not_active IP Right Cessation
- 1999-06-08 JP JP2000553128A patent/JP2002517468A/ja not_active Ceased
- 1999-06-08 CA CA2321700A patent/CA2321700C/en not_active Expired - Fee Related
- 1999-06-08 US US09/445,571 patent/US6348447B1/en not_active Expired - Lifetime
- 1999-06-08 PL PL343104A patent/PL198802B1/pl not_active IP Right Cessation
- 1999-06-08 WO PCT/SE1999/000997 patent/WO1999064060A1/en not_active Ceased
- 1999-06-08 DK DK99930089T patent/DK1094834T3/da active
- 1999-06-08 EP EP99930089A patent/EP1094834B1/en not_active Expired - Lifetime
- 1999-06-08 HU HU0103147A patent/HUP0103147A3/hu unknown
2000
- 2000-08-10 ZA ZA200004080A patent/ZA200004080B/xx unknown
- 2000-12-06 NO NO20006194A patent/NO327738B1/no not_active IP Right Cessation
2010
- 2010-07-01 JP JP2010151403A patent/JP2010270125A/ja active Pending

Also Published As

Publication number	Publication date
HUP0103147A2 (hu)	2002-01-28
CA2321700A1 (en)	1999-12-16
DE69912434D1 (de)	2003-12-04
PL198802B1 (pl)	2008-07-31
PL343104A1 (en)	2001-07-30
AU738994B2 (en)	2001-10-04
NO327738B1 (no)	2009-09-14
US6348447B1 (en)	2002-02-19
DK1094834T3 (da)	2004-01-05
EP1405642A1 (en)	2004-04-07
NZ506163A (en)	2004-10-29
RU2226402C2 (ru)	2004-04-10
CZ20004491A3 (en)	2001-05-16
HUP0103147A3 (en)	2002-02-28
DE69912434T2 (de)	2004-05-06
ATE252912T1 (de)	2003-11-15
CZ300873B6 (cs)	2009-09-02
JP2002517468A (ja)	2002-06-18
WO1999064060A1 (en)	1999-12-16
EP1094834B1 (en)	2003-10-29
JP2010270125A (ja)	2010-12-02
EP1094834A1 (en)	2001-05-02
AU4669799A (en)	1999-12-30
SE9802080D0 (sv)	1998-06-11
PT1094834E (pt)	2004-03-31
ES2205845T3 (es)	2004-05-01
NO20006194L (no)	2001-01-25
ZA200004080B (en)	2001-12-24
CA2321700C (en)	2011-05-03

Legal Events

Date	Code	Title	Description
2013-02-04	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO20006194D0 (no)	2000-12-06	Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
RU2000133249A (ru)	2002-11-27	Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
NO984005L (no)	1998-08-31	Anvendelse av et farmas°ytisk preparat som omfatter et appetittundertrykkende peptid
FI954941A7 (fi)	1996-04-19	Glukagonintapaisia insuliinitrooppisia peptidianalogeja, koostumuksia ja käyttömenetelmiä
BR0212080A (pt)	2006-04-04	composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
KR950002785A (ko)	1995-02-16	골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE316100T1 (de)	2006-02-15	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
WO2001068112A3 (en)	2002-03-07	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
NZ334270A (en)	2000-07-28	Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
NO20041203L (no)	2004-06-10	Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.
ATE182078T1 (de)	1999-07-15	Laxiermittel das ballastfasern und dioctyl- sulfosuccinat enthält
BR0308904A (pt)	2005-05-03	Método de tratamento de gastroparesia, e, uso de um composto de glp-1
FI943028L (fi)	1994-06-22	Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
IS1966B (is)	2004-12-15	Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
DE69011618D1 (de)	1994-09-22	Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
AU3733295A (en)	1996-05-02	Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
WO2003092619A3 (en)	2004-10-07	Prevention and treatment of type 2 diabetes
AU4927700A (en)	2000-12-28	Method for treating endotoxic shock and inflammatory and autoimmune diseases in mammals
Bhatt et al.	2005	Appliccitions of external fixator devices in Post Burn Contracture of extremities
马连生 et al.	1994	COMBINATION OF TRADITIONAL CHINESE MEDICINE AND WESTERN MEDICINE IN THE TREATMENT OF RESISTANT PEPTIC ULCER
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos
RU93032468A (ru)	1996-04-10	Способ лечения мышечно-тонического и нейро-дистрофического синдрома шейного и грудного остеохондроза
UA42351A (uk)	2001-10-15	Спосіб лікування туберкульозу